艾伯维公司宣布欧盟委员会批准Skyrizi®(瑞莎珠单抗)用于治疗中重度斑块状银屑病儿科患者

美股速递
Jun 23

艾伯维公司宣布,其药物Skyrizi®(通用名:瑞莎珠单抗)已获得欧盟委员会的批准,用于治疗中重度斑块状银屑病的儿科患者。这一监管批准为患有该慢性皮肤疾病的儿童和青少年提供了一个新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10